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Arthropodborne viruses (arboviruses) are transmitted to 
humans primarily through the bites of infected mosquitoes 
and ticks. West Nile virus (WNV) is the leading cause of 
domestically acquired arboviral disease in the continental 
United States (1). Other arboviruses, including eastern equine 
encephalitis, Jamestown Canyon, La Crosse, Powassan, and St. 
Louis encephalitis viruses, cause sporadic cases of disease and 
occasional outbreaks. This report summarizes surveillance data 
reported to CDC for 2018 on nationally notifiable arboviruses. 
It excludes dengue, chikungunya, and Zika viruses because they 
are primarily nondomestic viruses typically acquired through 
travel. In 2018, 48 states and the District of Columbia (DC) 
reported 2,813 cases of domestic arboviral disease, including 
2,647 (94%) WNV disease cases. Of the WNV disease cases, 
1,658 (63%) were classified as neuroinvasive disease (e.g., 
meningitis, encephalitis, and acute flaccid paralysis), for a 
national incidence of 0.51 cases of WNV neuroinvasive disease 
per 100,000 population. Because arboviral diseases continue to 
cause serious illness and have no definitive treatment, maintain-
ing surveillance is important to direct and promote prevention 
activities. Health care providers should consider arboviral 
infections in patients with aseptic meningitis or encephalitis, 
perform appropriate diagnostic testing, and report cases to 
public health authorities.
Arboviruses are maintained in a transmission cycle between 
arthropods and vertebrate hosts, including humans and other 
animals (2). Humans primarily become infected when bitten by 
an infected mosquito (West Nile, La Crosse, Jamestown Canyon, 
St Louis encephalitis, and eastern equine encephalitis viruses) or 
tick (Powassan virus). Most human infections are asymptomatic; 
symptomatic infections commonly manifest as a systemic febrile 
illness and less commonly as neuroinvasive disease.
Most endemic arboviral diseases are nationally notifiable 
and are reported by state health departments to CDC through 
ArboNET, the national arbovirus surveillance system, using 
standard surveillance case definitions that include clinical and 
laboratory criteria (3). Cases are reported by the patient’s state 
of residence. Confirmed and probable cases were included in 
this analysis. Cases reported as acute flaccid paralysis, encepha-
litis, meningitis, or an unspecified neurologic presentation 
were classified as neuroinvasive disease; cases with more than 
one neuroinvasive presentation were counted once according 
to the order specified above. Other clinical presentations were 
considered nonneuroinvasive disease. Incidence rates were cal-
culated using neuroinvasive disease cases and the U.S. Census 
2018 midyear population estimates.
A total of 2,813 cases of domestic arboviral disease were 
reported to CDC for 2018. Cases were caused by WNV 
(2,647 cases, 94%), La Crosse virus (86), Jamestown Canyon 
virus (41), Powassan virus (21), St. Louis encephalitis virus 
(eight), eastern equine encephalitis virus (six), and unspecified 
California serogroup virus (four). Cases were reported from 
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all states except Hawaii and New Hampshire. Of the 3,142 
U.S. counties, 858 (27%) reported one or more arboviral 
disease cases.
Overall, 2,647 WNV disease cases were reported from 787 
counties in 48 states and DC. Of these, 1,658 (63%) cases 
were neuroinvasive and 2,435 (92%) patients had illness onset 
during July–September (Table 1). In 2018, WNV disease was 
reported for the first time from a resident of Alaska; however, 
the patient’s likely location of infection was reported as a state 
with previously documented transmission. Two WNV disease 
cases were reported in solid organ transplant recipients with a 
common donor, and subsequent investigation demonstrated 
transmission via organ transplantation. The median age of 
patients with WNV disease was 59 years (interquartile range 
[IQR] = 44–70); 1,638 (62%) were male. A total of 1,774 
(67%) patients were hospitalized, and 167 (6%) died. The 
median age of patients who died was 74 years (IQR = 67–82).
Among the 1,658 WNV neuroinvasive cases, 908 (55%) 
were reported as encephalitis, 542 (33%) as meningitis, 70 
(4%) as acute flaccid paralysis, and 138 (8%) as an unspeci-
fied neurologic presentation. Of the 70 patients with acute 
flaccid paralysis, 25 (36%) also had encephalitis or meningitis. 
Among patients with neuroinvasive disease, 1,541 (93%) were 
hospitalized and 165 (10%) died. The incidence of WNV neu-
roinvasive disease in the United States was 0.51 per 100,000 
population (Table 2). The highest incidence rates occurred in 
North Dakota (7.89 per 100,000), Nebraska (6.43), South 
Dakota (5.33), Montana (2.35), and Iowa (1.87) (Figure). The 
largest number of cases were reported from California (154), 
Illinois (126), Nebraska (124), Texas (108), and Pennsylvania 
(95), which together accounted for nearly 37% of neuroinva-
sive disease cases. The incidence of WNV neuroinvasive disease 
increased with age group, from 0.03 per 100,000 in children 
aged <10 years to 1.66 in adults aged ≥70 years. Incidence was 
higher among males (0.65 per 100,000) than among females 
(0.36 per 100,000).
La Crosse virus disease cases (86) were reported from seven 
states, primarily in the East North Central and South Atlantic 
divisions (Table 2). La Crosse virus disease was reported 
for the first time in a Rhode Island resident; however, the 
patient’s likely location of infection was reported as a state 
with previously documented transmission. The median age 
of patients was 8 years (IQR = 5–12), and 81 (94%) were 
aged <18 years (Table 1). Illness onset dates ranged from 
May through October, with 61 (71%) reporting onset during 
July–September. Eighty-three (97%) cases were neuroinvasive, 
and 82 (95%) patients were hospitalized; no cases were fatal.
Jamestown Canyon virus disease cases (41) were reported 
from eight states, primarily in the East North Central and West 
North Central divisions (Table 2). Jamestown Canyon virus 
disease cases were reported for the first time from Connecticut 
and Michigan. The median age of patients was 53 years 
(IQR = 40–65), and 35 (85%) were male (Table 1). Illness 
onset ranged from April through November, with 26 (63%) 
reporting onset during July–September. Twenty-five (61%) 
cases were neuroinvasive, 30 (73%) patients were hospitalized, 
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and one (2%) patient with neuroinvasive disease died. The 
incidence of Jamestown Canyon virus neuroinvasive disease 
was highest in Wisconsin (0.22 per 100,000).
Powassan virus disease cases (21) were reported from eight 
states, primarily in the New England and Middle Atlantic 
divisions (Table 2). Powassan virus disease was reported for 
the first time from Indiana; however, transfusion of a blood 
product originating from a viremic donor in Wisconsin was 
the likely source of infection. The median age of patients was 
67 years (IQR = 53–74), and 14 (67%) were male (Table 1). 
Illness onset dates ranged from March through December, 
with 11 (52%) reporting onset during April–June. All 21 cases 
were neuroinvasive and resulted in hospitalization, including 
one (5%) pediatric case. Three (14%) patients died; all were 
aged >60 years.
Eight cases of St. Louis encephalitis virus disease were 
reported from four states (California, Georgia, Pennsylvania, 
and Wisconsin) (Table 2). The median age of patients was 
68 years (IQR = 50–76), and four were male (Table 1). Illness 
onset dates ranged from July through October, with four 
patients reporting onset in October. Five cases were neuroin-
vasive, and all five patients were hospitalized; one patient died.
Six cases of eastern equine encephalitis virus disease were 
reported from four states (Florida, Georgia, Michigan, and 
Pennsylvania) (Table 2). The median age of patients was 
64 years (IQR = 58–71), and three were male. Illness onset 
dates ranged from May through September, with four patients 
reporting onset during July–September. All cases were neuro-
invasive, and five patients were hospitalized; one patient died.
TABLE 1. Selected characteristics of reported cases of West Nile virus and other arboviral diseases, by virus type — United States, 2018
Characteristic
Virus, no. (%)
West Nile*  
(N = 2,647)
La Crosse  
(N = 86)
Jamestown  
Canyon  
(N = 41)
Powassan 
 (N = 21)
St. Louis  
encephalitis  
(N = 8)
Eastern equine 
encephalitis  
(N = 6)
Age group (yrs)
<18 58 (2) 81 (94) 1 (2) 1 (5) 0 (0) 0 (0)
18–59 1,281 (48) 4 (5) 25 (61) 6 (29) 3 (38) 2 (33)
≥60 1,308 (49) 1 (1) 15 (37) 14 (67) 5 (63) 4 (67)
Sex
Male 1,638 (62) 43 (50) 35 (85) 14 (67) 4 (50) 3 (50)
Female 1,009 (38) 43 (50) 6 (15) 7 (33) 4 (50) 3 (50)
Period of illness onset
January–March 4 (<1) 0 (0) 0 (0) 1 (5) 0 (0) 0 (0)
April–June 37 (1) 10 (12) 9 (22) 11 (52) 0 (0) 2 (33)
July–September 2,435 (92) 61 (71) 26 (63) 5 (24) 4 (50) 4 (67)
October–December 170 (6) 15 (17) 6 (15) 4 (19) 4 (50) 0 (0)
Clinical syndrome
Nonneuroinvasive 989 (37) 3 (3) 16 (39) 0 (0) 3 (38) 0 (0)
Neuroinvasive 1,658 (63) 83 (97) 25 (61) 21 (100) 5 (62) 6 (100)
Encephalitis 908 (34) 70 (81) 11 (27) 15 (71) 3 (38) 6 (100)
Meningitis 542 (20) 13 (15) 7 (17) 5 (24) 1 (13) 0 (0)
Acute flaccid paralysis 70 (3) 0 (0) 4 (10) 0 (0) 0 (0) 0 (0)
Unspecified 138 (5) 0 (0) 3 (7) 1 (5) 1 (13) 0 (0)
Outcome
Hospitalization 1,774 (67) 82 (95) 30 (73) 21 (100) 5 (63) 5 (83)
Death 167 (6) 0 (0) 1 (2) 3 (14) 1 (13) 1 (17)
* Date of illness onset missing for one case of West Nile virus.
FIGURE. Incidence* of reported cases of West Nile virus neuroinvasive 
disease — United States, 2018
0.00
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DC
Abbreviation: DC = District of Columbia.
* Cases per 100,000 population.
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TABLE 2. Number and rate* of reported cases of arboviral neuroinvasive disease, by virus type, U.S. Census division, and state — United States, 2018
U.S. Census division/
State
Virus, no. (rate)
West Nile La Crosse Jamestown Canyon Powassan St. Louis encephalitis Eastern equine encephalitis
United States 1,658 (0.51) 83 (0.03) 25 (0.01) 21 (0.01) 5 (<0.01) 6 (<0.01)
New England 62 (0.42) 1 (<0.01) 3 (0.02) 8 (0.05) —† —
Connecticut 18 (0.50) — 1 (0.03) 2 (0.06) — —
Maine 1 (0.07) — 1 (0.07) — — —
Massachusetts 42 (0.61) — 1 (0.01) 6 (0.09) — —
New Hampshire — — — — — —
Rhode Island — 1§ (0.09) — — — —
Vermont 1 (0.16) — — — — —
Middle Atlantic 216 (0.52) — — 6 (0.01) — 1 (<0.01)
New Jersey 44 (0.49) — — 1 (0.01) — —
New York 77 (0.39) — — 4 (0.02) — —
Pennsylvania 95 (0.74) — — 1 (<0.01) — 1 (<0.01)
East North Central 306 (0.65) 38 (0.08) 14 (0.03) 4 (<0.01) 1 (<0.01) 1 (<0.01)
Illinois 126 (0.99) — — — — —
Indiana 26 (0.39) — — 1¶ (0.01) — —
Michigan 80 (0.80) — 1 (0.01) — — 1 (0.01)
Ohio 45 (0.38) 38 (0.33) — — — —
Wisconsin 29 (0.50) — 13 (0.22) 3 (0.05) 1 (0.02) —
West North Central 364 (1.70) — 7 (0.03) 3 (0.01) — —
Iowa 59 (1.87) — — — — —
Kansas 23 (0.79) — — — — —
Minnesota 34 (0.61) — 7 (0.12) 3 (0.05) — —
Missouri 17 (0.28) — — — — —
Nebraska 124 (6.43) — — — — —
North Dakota 60 (7.89) — — — — —
South Dakota 47 (5.33) — — — — —
South Atlantic 172 (0.26) 31 (0.05) — — — 4 (<0.01)
Delaware 8 (0.83) — — — — —
District of Columbia 7 (1.00) — — — — —
Florida 30 (0.14) — — — — 3 (0.01)
Georgia 30 (0.29) — — — — 1 (<0.01)
Maryland 35 (0.58) — — — — —
North Carolina 10 (0.10) 24 (0.23) — — — —
South Carolina 12 (0.24) — — — — —
Virginia 38 (0.45) 2 (0.02) — — — —
West Virginia 2 (0.11) 5 (0.28) — — — —
East South Central 67 (0.35) 12 (0.06) 1 (<0.01) — — —
Alabama 16 (0.33) — — — — —
Kentucky 9 (0.20) — — — — —
Mississippi 31 (1.04) — — — — —
Tennessee 11 (0.16) 12 (0.18) 1 (0.01) — — —
West South Central 182 (0.45) 1 (<0.01) — — — —
Arkansas 6 (0.20) — — — — —
Louisiana 56 (1.20) — — — — —
Oklahoma 12 (0.30) — — — — —
Texas 108 (0.38) 1 (<0.01) — — — —
Mountain 130 (0.53) — — — — —
Arizona 25 (0.35) — — — — —
Colorado 52 (0.91) — — — — —
Idaho 10 (0.57) — — — — —
Montana 25 (2.35) — — — — —
Nevada 3 (0.10) — — — — —
New Mexico 5 (0.24) — — — — —
Utah 7 (0.22) — — — — —
Wyoming 3 (0.52) — — — — —
Pacific 159 (0.30) — — — 4 (<0.01) —
Alaska 1§ (0.14) — — — — —
California 154 (0.39) — — — 4 (0.01) —
Hawaii — — — — — —
Oregon 2 (0.05) — — — — —
Washington 2 (0.03) — — — — —
* Per 100,000 population, based on July 1, 2018, U.S. Census population estimates.
† Dashes indicate none reported.
§ Patient reported travel to a state with a history of the virus. 
¶ Patient acquired infection through blood transfusion.
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Discussion
As in previous years, WNV was the most common cause of 
neuroinvasive arboviral disease in the United States, accounting 
for 92% of reported neuroinvasive disease cases. The incidence 
of WNV neuroinvasive disease in 2018 (0.51 per 100,000) was 
nearly 25% higher than the median incidence of 0.41 during 
2008–2017 (range = 0.13 [2009]–0.92 [2012]) (4). Multiple 
western states with historically large numbers of cases (e.g., 
Arizona and California) reported below average incidences 
in 2018, and multiple northeastern states (e.g., New Jersey, 
New York, and Pennsylvania) experienced higher incidences 
than usual.
More La Crosse virus disease cases were reported in 2018 
than in any year since 2011 (5), and La Crosse virus continued 
to be the most common cause of neuroinvasive arboviral disease 
in children (6). Arboviruses were an ongoing concern for blood 
and tissue safety, because the first documented case of Powassan 
virus transmission via blood transfusion was reported (7), and 
two WNV disease cases in solid organ recipients from a single 
donor were the first transplant-transmitted cases reported since 
2013 (8). Fewer cases of Jamestown Canyon virus disease 
were reported in 2018 than in 2017; however, the number of 
cases reported was still higher than that in other years before 
2017 (9). Although increased activity of the virus cannot be 
ruled out, the recent increase in cases might be attributable 
to a known increase in awareness and testing, particularly 
in the upper Midwest. The epidemiology of eastern equine 
encephalitis and St. Louis encephalitis cases was consistent 
with previous years.
Although the reported number of cases varies annually, arbo-
viruses continue to cause substantial morbidity in the United 
States. Cases occur sporadically, and the epidemiology varies 
by virus and geography. Approximately 93% of arboviral dis-
ease cases occurred during April–September in 2018, which is 
consistent with the peak season in past years. Weather, zoonotic 
host, vector abundance, and human behavior all influence 
when and where arboviral disease outbreaks occur. These fac-
tors make it difficult to predict locations and timing of future 
cases and highlight the importance of surveillance in identify-
ing outbreaks and informing public health prevention efforts.
The findings in this report are subject to at least two 
limitations. First, ArboNET is a passive surveillance system 
that underreports the actual incidence of disease. Detection 
and reporting of neuroinvasive disease are considered more 
consistent and complete than that of nonneuroinvasive dis-
ease. Previous studies have estimated that between 30 and 70 
nonneuroinvasive disease cases occur for every case of WNV 
neuroinvasive disease reported (10). Based on the number of 
neuroinvasive disease cases reported for 2018, between 49,740 
and 116,060 nonneuroinvasive disease cases of WNV would 
have been expected to occur; however, only 989 (1%–2%) 
were reported. Second, because ArboNET does not require 
information about clinical signs and symptoms or laboratory 
findings, cases might be misclassified.
Health care providers should consider arboviral infections 
in the differential diagnosis of aseptic meningitis or encepha-
litis, obtain appropriate specimens for laboratory testing, 
and promptly report cases to public health authorities (2,3). 
Understanding the epidemiology, seasonality, and geographic 
distribution of these arboviruses is important for clinical rec-
ognition and differentiation from other neurologic infections. 
Because human vaccines against domestic arboviruses are not 
available, prevention depends on community and household 
efforts to reduce vector populations, personal protective mea-
sures to decrease mosquito and tick exposures, and blood dona-
tion screening to minimize alternative routes of transmission.
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Summary
What is already known about this topic?
West Nile virus (WNV) is consistently the leading cause of 
domestically acquired arboviral disease, but other arboviruses 
cause sporadic cases and outbreaks of neuroinvasive disease.
What is added by this report?
WNV neuroinvasive disease incidence was nearly 25% higher in 
2018 than the median incidence during 2008–2017. WNV 
transmission via organ transplantation was reported for the first 
time since 2013. The first documented case of Powassan virus 
transmission via blood transfusion was reported.
What are the implications for public health practice?
Health care providers should consider arboviral infections in 
patients with aseptic meningitis or encephalitis, perform 
appropriate diagnostic testing, and report cases to public 
health authorities. Surveillance helps to identify outbreaks and 
guide prevention strategies.
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